

VERTEX PHARMACEUTICALS INC / MA

Form 4

November 28, 2007

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BOGER JOSHUA S**

2. Issuer Name and Ticker or Trading Symbol  
**VERTEX PHARMACEUTICALS INC / MA [VRTX]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
11/27/2007

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President & CEO

C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

CAMBRIDGE, MA 02139

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/27/2007		M		17,500	A	\$ 13.67
Common Stock	11/27/2007		S <sup>(1)(2)</sup>		200	D	\$ 24.52
Common Stock	11/27/2007		S <sup>(1)(3)</sup>		3,800	D	\$ 24.44
Common Stock	11/27/2007		S <sup>(1)(4)</sup>		3,800	D	\$ 24.34

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	11/27/2007	<u>S<sup>(1)(5)</sup></u>	2,000	D	\$ 24.23	1,103,542	D	
Common Stock	11/27/2007	<u>S<sup>(1)(6)</sup></u>	1,500	D	\$ 24.16	1,102,042	D	
Common Stock	11/27/2007	<u>S<sup>(1)(7)</sup></u>	2,900	D	\$ 24.05	1,099,142	D	
Common Stock	11/27/2007	<u>S<sup>(1)(8)</sup></u>	1,100	D	\$ 23.95	1,098,042	D	
Common Stock	11/27/2007	<u>S<sup>(1)(9)</sup></u>	1,000	D	\$ 23.84	1,097,042	D	
Common Stock	11/27/2007	<u>S<sup>(1)(10)</sup></u>	700	D	\$ 23.75	1,096,342	D	
Common Stock	11/27/2007	<u>S<sup>(1)(11)</sup></u>	500	D	\$ 23.65	1,095,842	D	
Common Stock						12,445	I	401(k)
Common Stock						207,500	I	Shares in trust <u>(13)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option	\$ 13.67	11/27/2007		M	17,500	<u>(12)</u> 12/11/2007	Common Stock	17,500

## Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Director      10% Owner      Officer      Other

BOGER JOSHUA S  
 C/O VERTEX PHARMACEUTICALS INCORPORATED  
 130 WAVERLY STREET  
 CAMBRIDGE, MA 02139

X      President  
 & CEO

## Signatures

Valerie L. Andrews,      11/28/2007  
 Attorney-In-Fact

    Signature of Reporting Person      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- (2) Aggregate sales made at prices between \$24.51 and \$24.53.
- (3) Aggregate sales made at prices between \$24.40 and \$24.49.
- (4) Aggregate sales made at prices between \$24.30 and \$23.39.
- (5) Aggregate sales made at prices between \$24.20 and \$24.29.
- (6) Aggregate sales made at prices between \$24.11 and \$24.19.
- (7) Aggregate sales made at prices between \$24.00 and \$24.09.
- (8) Aggregate sales made at prices between \$23.90 and \$23.99.
- (9) Aggregate sales made at prices between \$23.81 and \$23.87.
- (10) Aggregate sales made at prices between \$23.71 and \$23.78.
- (11) Aggregate sales made at prices between \$23.59 and \$23.68.
- (12) Fully vested.
- (13) Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.  
 Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.